List of On-going Recruiting Trials in HKU Department of Clinical Oncology
Protocol No. Trial name Cancer Site Experimental Treatment Agent Key Eligibility Criteria PI Study Coordinator Contact  
TS102 A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy Colorectal cancer with liver-limited metastases TheraSphere® 2nd line treatment after failure 1st line chemotherapy (irinotecan-based/oxaliplatin-based) Dr Victor Lee Angela Li
2255 5362
UW15-429
(ADAURA)
A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) Lung AZD9291 Adjuvant AZD9291 for 3 years after adjuvant chemotherapy for lung cancer Dr Victor Lee Sandy Cheung
2255 5034
MK3475-122 A Two-arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK3475) Monotherapy versus Standard Chemotherapy in Platium Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) Nasopharyngeal Cancer Pembrolizumab For patient with locally advanced recurrent or metastatic NPC patient who received at least one line of platium-based chemotherapy Dr Victor Lee Angela Li
2255 5362
CanStem303C A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Audit Patients with Previously Treated Metastatic Colorectal Cancer (CRC) Colorectal Cancer BBI-608 1st line treatment must contain fluoropyrimidine and oxaliplatin with or without bevacizumab Dr Lam Ka On Sandy Cheung
2255 5034
CA209649 A Radomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus lpilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Perviously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer GEJ / Gastric Nivolumab lpilimumab 1st line treatment for inoperable, advanced or metastatic GC or GEJ carcinoma, Her2 -ve Dr Lam Ka On Sandy Cheung / Crystal Chan
2255 5124
CA209648 A Radomized Phase 3 Study of Nivolumab plus lpilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma Nivolumab lpilimumab 1st line treatment for Advanced, Recurrent or Metastatic ESCC Dr Lam Ka On Sandy Cheung / Crystal Chan
2255 5124
B7461006 A Phase, Randomized, Open-label study of Lortatinib (PF-06463922) Monotherapy Versus Crizontinib Monotherapy in the First-line Treatment of Patients with Advanced ALK-Positive Non-small Cell Lung Cancer NSCLC Lorlatinib 1st line treatment for ALK +ve NSCLC Dr Victor Lee Sandy Cheung / Angela Li
2255 5034
X-covery Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients Lung X-396 Histologically or ctyologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive. Patients may have received up to 1 prior chemotherapy regimen, which may also include maintenance therapy Dr Victor Lee Kenneth Chan
2255 5124
MK3475-590 A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590) Esophagus Pembrolizumab 1st line treatment for patient with histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert Type 1 adenocarcinoma of EGJ Professor Dora Kwong Jenny Wong
2255 4216
AB12003 A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of Masitinib in combination with Docetaxel to placebo in combination with Docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC) Prostate Cancer Masitnib Masitinib/placebo + Docetaxol / Ca Prostate / Chemo naive, indication for chemo Dr Steven Siu Satcia Chun
2255 6220
WO30070 A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti PD-L1 Antibody) in Combination With Gemcitabline/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Untreated Locally Advanced or Metastatic Urotherlial Carcinoma Who Are lneligible For Cisplatin-Based Therapy Urothelial Ca Atezolizumab Atezolizumab/placebo + GC or Atezo open label monotherapy / Urothelial Ca / first line chemo naive (or relapse adj. progression free period > 1yr) Dr Steven Siu Satcia Chun
2255 6220
MK3475-199 Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199) Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pembrolizumab Pembrolizumab open label + SFL enzalutaminde / Ca Prostate / chemo naive, PD upon Enzalutaminde with measurable lesion Dr Steven Siu Satcia Chun
2255 6220
IMU.ACS.001 A Phase 1b/2 Open-label Study of IMU-131 HER2/neu Peptide Vaccine Plus Cisplatin and either 5-Fluorouracil or Capecitabine Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Stomach / GEJ Cancer IMU-131 HER2/neu Peptide Vaccine HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Dr Lam Ka On Please contact Dr Lam directly for further information